Ignite Creation Date:
2025-12-24 @ 6:41 PM
Ignite Modification Date:
2026-02-22 @ 4:15 PM
Study NCT ID:
NCT02103257
Status:
UNKNOWN
Last Update Posted:
2015-04-29
First Post:
2014-03-31
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma
Sponsor:
Betta Pharmaceuticals Co., Ltd.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
BD-IC-IV62
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None